Get the Stockscreener App
68.93
1.50%
-1.05
Pre-market:
70.01
1.08
+1.57%
Soleno Therapeutics Inc stock is traded at $68.93, with a volume of 612.97K.
It is down -1.50% in the last 24 hours and up +40.36% over the past month.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
See More
Previous Close:
$69.98
Open:
$68.44
24h Volume:
612.97K
Relative Volume:
0.57
Market Cap:
$3.21B
Revenue:
-
Net Income/Loss:
$-38.99M
P/E Ratio:
-23.00
EPS:
-2.9966
Net Cash Flow:
$-24.94M
1W Performance:
-1.53%
1M Performance:
+40.36%
6M Performance:
+28.24%
1Y Performance:
+83.81%
1-Day Range:
$68.30
$71.15
1-Week Range:
$68.27
$71.15
52-Week Range:
$36.93
$74.00
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Name
Soleno Therapeutics Inc
Sector
Industry
Phone
650-213-8444
Address
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
68.93 | 3.21B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Resumed | Stifel | Buy |
| Dec-02-24 | Reiterated | Robert W. Baird | Outperform |
| Dec-02-24 | Reiterated | Stifel | Buy |
| Sep-03-24 | Initiated | H.C. Wainwright | Buy |
| May-10-24 | Initiated | Robert W. Baird | Outperform |
| Feb-05-24 | Initiated | Piper Sandler | Overweight |
| Jan-23-24 | Initiated | Stifel | Buy |
| Nov-21-23 | Resumed | Guggenheim | Buy |
| Sep-29-20 | Initiated | Guggenheim | Buy |
| Jan-10-20 | Initiated | Craig Hallum | Buy |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
View All
Soleno Therapeutics Inc Stock (SLNO) Latest News
How To Trade (SLNO) - news.stocktradersdaily.com
Soleno Therapeutics appoints CBIZ CPAs as new auditor By Investing.com - Investing.com Nigeria
Soleno Therapeutics appoints CBIZ CPAs as new auditor - Investing.com Australia
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Acquired by Geode Capital Management LLC - Defense World
Franklin Resources Inc. Takes Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Soleno launches Vykat XR (SLNO:NASDAQ) - Seeking Alpha
Soleno Therapeutics launches FDA-approved PWS treatment By Investing.com - Investing.com South Africa
Soleno Launches Pill For Hyperphagia In Prader-Willi Syndrome Patients But Retail’s Unmoved - MSN
Soleno Therapeutics launches FDA-approved PWS treatment - Investing.com
Soleno Therapeutics Announces VYKAT(TM) XR Launch - GlobeNewswire
Breakthrough PWS Treatment VYKAT XR Now Available: First-Ever FDA Approval for Rare Disease - Stock Titan
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug - MSN
KLP Kapitalforvaltning AS Takes Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Soleno Therapeutics (SLNO) Gains FDA Approval for Prader-Willi T - GuruFocus
SLNO Quantitative Stock Analysis - Nasdaq
Capnia Inc stock soars to 52-week high, hits $74 mark - Investing.com
Soleno therapeutics SVP sells $265,156 in stock By Investing.com - Investing.com Australia
Soleno therapeutics SVP sells $265,156 in stock - Investing.com
Soleno Therapeutics, Inc. (NASDAQ:SLNO) CEO Bhatnagar Anish Sells 699,095 Shares - MarketBeat
Piper Sandler maintains $93 target on Soleno stock post-VYKAT XR nod By Investing.com - Investing.com South Africa
Piper Sandler maintains $93 target on Soleno stock post-VYKAT XR nod - Investing.com
High Growth Tech Stocks To Watch In The US April 2025 - simplywall.st
Soleno Therapeutics CEO sells $35.3 million in stock By Investing.com - Investing.com Philippines
Soleno Therapeutics CEO sells $35.3 million in stock - Investing.com Australia
Soleno Therapeutics CEO Anish Bhatnagar sells $35.3m in stock - Investing.com Australia
Soleno Therapeutics CEO Anish Bhatnagar sells $35.3m in stock By Investing.com - Investing.com Nigeria
Soleno Therapeutics exec sells shares worth $9.5 million By Investing.com - Investing.com South Africa
Soleno therapeutics director Matthew Pauls sells $424,797 in stock By Investing.com - Investing.com Canada
Soleno therapeutics’ SVP Yen Kristen sells $4.88 million in stock - Investing.com India
Soleno therapeutics director Matthew Pauls sells $424,797 in stock - Investing.com Australia
Soleno Therapeutics exec sells $700,330 in stock - Investing.com India
Soleno Therapeutics CFO sells $4.88 million in stock - Investing.com Australia
Soleno Therapeutics Executives and Director Sell Shares - TradingView
Soleno Therapeutics CCO sells shares worth $2.48m - Investing.com
Soleno therapeutics’ SVP Yen Kristen sells $4.88 million in stock By Investing.com - Investing.com UK
Soleno Therapeutics CCO sells shares worth $2.48m By Investing.com - Investing.com UK
Soleno Therapeutics CFO sells $4.88 million in stock By Investing.com - Investing.com UK
Soleno Therapeutics Executives Sell Shares - TradingView
Soleno Therapeutics exec sells shares worth $9.5 million - Investing.com
Soleno Therapeutics’ SWOT analysis: FDA approval boosts rare disease stock - Investing.com Australia
Soleno stock price target raised to $100 at H.C. Wainwright By Investing.com - Investing.com South Africa
Soleno stock price target raised to $100 at H.C. Wainwright - Investing.com
Soleno Therapeutics’ SWOT analysis: FDA approval boosts rare disease stock By Investing.com - Investing.com South Africa
Soleno Therapeutics Stock (SLNO) Surges on FDA Green Light for PWS Treatment - Markets Insider
Why Soleno Therapeutics Inc. (SLNO) Went Up Last Week? - Insider Monkey
10 Stocks Outperform Broader Market Last Week - Insider Monkey
Soleno Therapeutics Inc Stock (SLNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):